24
total announcements
AARTIDRUGS.NS · 15 min delayed
Aarti Drugs Limited
Aarti Drugs Limited has informed the Exchange about the completion of dispatch of Annual Report for the Financial Year 2025-26 and the Notice of the 41st Annual General Meeting scheduled to be held on September 26, 2026.
Aarti Drugs Limited
Aarti Drugs Limited has submitted its Business Responsibility and Sustainability Report for FY 2025-26, as required by SEBI regulations.
Aarti Drugs Limited
Aarti Drugs Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 26, 2026, along with the Annual Report for the Financial Year 2025-26.
Aarti Drugs Limited
Aarti Drugs Limited has informed the Exchange about a copy of newspaper publication regarding the 41st Annual General Meeting scheduled to be held on September 26, 2026.
Aarti Drugs Limited
Aarti Drugs Limited has informed the Exchange regarding Outcome of Board Meeting held on August 27, 2026, where the Board of Directors approved the 'Aarti Drugs Limited Performance Stock Option Plan 2026' to grant not exceeding 8,00,000 Performance Stock Options to eligible employees.
Aarti Drugs Limited
Aarti Drugs Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, from August 25, 2026, till August 29, 2026, ahead of a Board meeting on August 27, 2026, to consider the 'Aarti Drugs Limited – Performance Stock Option Plan 2026'.
Aarti Drugs Limited
Aarti Drugs Limited has informed the Exchange about the schedule of an analyst/institutional investor meeting on August 20, 2026, in Mumbai, where company officials will discuss publicly available information.
Aarti Drugs Limited
Aarti Drugs Limited has informed the Exchange that the Hon'ble Supreme Court of India has dismissed the Special Leave Petition filed by the GST Department, disposing of the matter in favour of the Company.
Aarti Drugs Limited
Aarti Drugs Limited has informed the Exchange about the transcript of Q1 FY27 Earning Conference call, which discussed the company's financial results and operational performance for the quarter ended 30th June 2026.
Aarti Drugs Limited
Aarti Drugs Limited has informed the Exchange about the schedule of an analyst/institutional investor meet.
Aarti Drugs Limited
Aarti Drugs Limited has informed the Exchange about the link of recording for the conference call regarding the financial results for the quarter ended June 30, 2026. The audio recording is available on the company's website.
Aarti Drugs Limited
Aarti Drugs Limited has published its standalone and consolidated financial results for the quarter ended June 30, 2026, in accordance with Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Aarti Drugs Limited
Aarti Drugs Limited has released its Q1 FY27 investor presentation, highlighting a strong operational and financial performance driven by volume growth, improved realizations, and disciplined execution. The company reported a 19% YoY increase in net revenue from operations, with EBITDA and PBT margins expanding by 120bps and 120bps, respectively. The company's management commentary attributed the performance to a recovery in the pricing environment and operational efficiencies.
Aarti Drugs Limited
Aarti Drugs Limited has announced its unaudited financial results for the quarter ended June 30, 2026, with revenue standing at Rs. 703.6 crore, a 19% YoY growth, and EBITDA at Rs. 96.9 crore, a 30% YoY growth.
Aarti Drugs Limited
Aarti Drugs Limited has received a revocation order from the Gujarat Pollution Control Board (GPCB) regarding a closure direction issued for its plant located at Sayakha. The GPCB has accepted the company's application and has issued a revocation order, permitting the company to continue its operations. An interim Environmental Damage Compensation (EDC) of Rs. 10,20,000 has been levied as an interim measure.
Aarti Drugs Limited
Aarti Drugs Limited has announced leadership transition with Shri Rashesh C. Gogri elevated as Chairman and Managing Director, and Shri Adhish P. Patil appointed as Managing Director, effective October 1, 2026, replacing Shri Prakash M. Patil who will retire as Chairman, Managing Director & CEO.
Aarti Drugs Limited
Aarti Drugs Limited has announced the retirement of its Chairman, Managing Director, and CEO, Prakash M. Patil, effective September 30, 2026, and the appointment of Rashesh C. Gogri as the new Chairman, and Adhish P. Patil as the new Managing Director, both effective October 1, 2026. The company has also announced the re-appointment of several directors, including Harshit M. Savla, Harit P. Shah, Hasmukh B. Dedhia, Ajit E. Venugopalan, and Sandeep M. Joshi, for a further term of 5 years.
Aarti Drugs Limited
Aarti Drugs Limited has announced its audited standalone and consolidated financial results for the quarter ended June 30, 2026, with a net profit of Rs. 5,085 lakhs and a revenue from operations of Rs. 70,278 lakhs.
Aarti Drugs Limited
Aarti Drugs Limited has informed the Exchange about the schedule of a conference call to discuss the company's financial performance for the quarter ended June 30, 2026.
Aarti Drugs Limited
Aarti Drugs Limited has received a Closure Directions letter from the Gujarat Pollution Control Board (GPCB) under Section 33A of the Water (Prevention and Control of Pollution) Act, 1974, mandating the closure of manufacturing operations at the Company’s plant located at Plot No. DP-94 to DP-96, Saykha Industrial Estate, Dist. Bharuch, Gujarat, effective 15 days from the date of issuance of the letter, alongside other related directions.